Sebaaly Camille 4
4 · Sunshine Biopharma, Inc · Filed Jul 15, 2020
Insider Transaction Report
Form 4
Sebaaly Camille
DirectorCFO and Secretary
Transactions
- Award
Common Stock
2019-09-11$0.00/sh+550,000$550→ 1,493,086 total - Award
Common Stock
2019-10-20$0.00/sh+1,100,000$1,100→ 2,593,086 total - Award
Common Stock
2019-12-19$0.00/sh+1,300,000$1,300→ 3,893,086 total - Award
Common Stock
2019-12-31$0.00/sh−323,673$324→ 0 total(indirect: Held by TRT Pharma Inc.)
Footnotes (3)
- [F1]The amount of Securities Acquired or Disposed of and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person.
- [F2]Shares issued by the Issuer to the Reporting Person for consulting services provided to the Issuer.
- [F3]Effective December 31, 2019, 4019318 Canada, Inc., an entity controlled by the Reporting Person, effectuated a consolidation with Advanomics Corporation, an entity controlled by the Chief Executive Officer of the Issuer. The resulting consolidated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. and the Reporting Person no longer being a control person of TRT Pharma Inc.